| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Statins Could Contribute to Decreased Risk of Aggressive Prostate Cancer: Presented at AUA By Karen Shoffner CHICAGO -- April 30, 2009 -- Statin users are found to have more favourable pathological features upon radical prostatectomy, researchers stated during a press briefing here at the 2009 American Urological Association (AUA) Annual Meeting. The favourable pathological features possibly associated with statin use include "a significantly lower prostate-specific antigen level at diagnosis, as well as a lower rate of positive surgical margins and lower tumour volume at radical prostatectomy," stated lead author Stacy Loeb, MD, Johns Hopkins Brady Urological Institute, Baltimore, Maryland, presenting study results here on April 26. From 2003 to 2008, a total of 1,282 men with data on preoperative statin use underwent radical prostatectomy by a single surgeon. Statistical analysis was used to compare clinicopathological features between 480 statin users and 802 nonusers. Statin users were significantly older and had a higher mean body mass index (BMI) than nonusers. Overall, statin users tended to have a lower proportion of adverse tumour features, including a significantly lower risk of positive surgical margins. Tumour volume was significantly lower in the radical prostatectomy specimen of patients using statins (5.06 vs 5.81; P = .035), as was the mean percentage of cancer (10.6% vs 12.0%; P = .048), and preoperative PSA levels. Overall, statin users had a lower proportion of adverse tumour features, including a lower risk of positive surgical margins (13.6% vs 18.2%; P = .035) The results suggest that the use of statins may be associated with more favourable pathological features at radical prostatectomy, but "these findings require further validation in prospective studies," Dr. Loeb noted. The association between statins and prostate cancer risk is controversial. Some studies have suggested that statin use may reduce the risk of aggressive prostate cancer; whereas, others have shown no difference in treatment outcomes based upon statin use. Funding for this study was provided by the Urological Research Foundation and Specialized Program of Research Excellence and Robert H. Lurie Comprehensive Cancer Center grants.
[Presentation title: Is Statin Use Associated With Prostate Cancer Aggressiveness? Abstract 576]
|